Fluoxetine, Serum
Fluoxetine is one of the selective serotonin reuptake inhibitors typically known as SSRIs, and belong to the class of drugs known as antidepressants. The SSRIs have become the first-line pharmaceutical treatment of depression in the United States and treat depression by increasing serotonergic activity. Other clinical uses of antidepressants are for disorders or clinical conditions such as obsessive-compulsive disorder, chronic pain, eating disorders, anxiety or panic disorders, peptic ulcer disease or childhood enuresis. The SSRIs typically do not elicit the anticholinergic side effects of the TCAs, are easier to tolerate, are not as toxic, and are safer for the patient. As occurs with most drugs, there are some side effects of SSRI use including anxiety, sleep disturbances, sexual dysfunction, and insomnia.
The SSRIs are lipophilic, have large volumes of distribution, are well absorbed in the gastrointestinal tract, and reach peak plasma concentrations within one to eight hours. Most SSRIs are metabolized by the cytochrome P450 system and many of the metabolites are pharmacologically active. Fluoxetine is metabolized to norfluoxetine which is also biologically active. The half-lives of these particular drugs are quite variable. The half-life of fluoxetine is between 26-168 hours. SSRI plasma concentrations are not routinely measured because they have not been show to correlate with clinical response.
The effects associated with fluoxetine abuse include hallucinations, tachycardia, seizures, nausea, vomiting, tremors, and coma when taken to excess.
In conclusion, SSRIs, including citalopram are frequently prescribed and therefore encountered drugs.
- Drug abuse evaluation
- Toxicity assessment
- Patient Compliance
- Potential identification of rapid metabolizers
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Antidepressant DEA Drug Fact Sheet.
- Levine, Barry (Ed). Therapeutic Drugs II: Antidepressants. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 403-420.
- Balant-Georgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther. 1992;14(4):612-4.
- Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
- Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
- Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
- Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
- Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
- Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6